2023
43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial
Strober B, Kivitz A, Östör A, Padilla B, Yue C, Photowala H, Merola J. 43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial. Journal Of The American Academy Of Dermatology 2023, 89: ab179. DOI: 10.1016/j.jaad.2023.07.717.Peer-Reviewed Original ResearchPOS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
Mcgonagle D, Kavanaugh A, Mcinnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS. 2023, 1124-1125. DOI: 10.1136/annrheumdis-2023-eular.5.Peer-Reviewed Original ResearchPOS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS
Coates L, Strober B, Yu J, Leibowitz E, Rowland K, Kollmeier A, Miller M, Wang Y, LI S, Chakravarty S, Chan D, Shawi M, Yang Y, Lebwohl M, Rahman P. POS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS. 2023, 1134-1135. DOI: 10.1136/annrheumdis-2023-eular.1917.Peer-Reviewed Original Research
2021
S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years
Long M, Danese S, Ott E, Gasink C, Miao Y, Baker T, Tikhonov I, Rahman P, Strober B, Loftus E. S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years. The American Journal Of Gastroenterology 2021, 116: s441-s441. DOI: 10.14309/01.ajg.0000777252.35443.aa.Peer-Reviewed Original Research
2019
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Ghosh S, Gensler L, Yang Z, Gasink C, Chakravarty S, Farahi K, Ramachandran P, Ott E, Strober B. Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety 2019, 42: 809-809. PMID: 31012051, PMCID: PMC6520476, DOI: 10.1007/s40264-019-00816-3.Peer-Reviewed Original ResearchUtilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
Mease P, Palmer J, Hur P, Strober B, Lebwohl M, Karki C, Reed G, Etzel C, Greenberg J, Helliwell P. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry. Journal Of The European Academy Of Dermatology And Venereology 2019, 33: 886-892. PMID: 30663130, PMCID: PMC6593969, DOI: 10.1111/jdv.15443.Peer-Reviewed Original ResearchConceptsPsoriasis Epidemiology Screening ToolRegistry patientsPsoriatic arthritisActivity impairmentWorse health-related qualityDermatology Life Quality IndexScreening toolCorrona Psoriasis RegistryUndiagnosed psoriatic arthritisHealth-related qualityPatient-reported outcomesLife Quality IndexWorse health statusFive-item questionnaireChi-squared testCross-sectional analysisPsoriasis RegistryClinical characteristicsHigher BMIPatientsHealth statusPSAPEST scoresCategorical variablesArthritis
2018
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
Warren R, Reich K, Langley R, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. British Journal Of Dermatology 2018, 179: 1205-1207. PMID: 29927479, DOI: 10.1111/bjd.16901.Peer-Reviewed Original Research
2014
Tumor necrosis factor inhibitors in psoriasis: an update.
Kerdel F, Strober B. Tumor necrosis factor inhibitors in psoriasis: an update. Seminars In Cutaneous Medicine And Surgery 2014, 33: s31-6. PMID: 24979543, DOI: 10.12788/j.sder.0066.Peer-Reviewed Original ResearchConceptsTumor necrosis factorTNF inhibitorsNecrosis factor inhibitorsTreatment of psoriasisCertolizumab pegolPlaque psoriasisPsoriatic arthritisFactor inhibitorsClinical trialsNecrosis factorPsoriasisRecent evidenceInhibitorsEfficacyGolimumabInfliximabPegolAdalimumabEtanerceptArthritisImmunogenicity
2012
Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases
de Souza A, Ali‐Shaw T, Reddy S, Fiorentino D, Strober B. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. British Journal Of Dermatology 2012, 168: 210-212. PMID: 23278559, DOI: 10.1111/j.1365-2133.2012.11206.x.Peer-Reviewed Original ResearchConceptsUstekinumab treatmentHuman immunoglobulin G1κ monoclonal antibodyChronic inflammatory skin conditionInflammatory skin conditionT helper 1Common p40 subunitT cell differentiationIL-23Inflammatory arthritisPsoriatic arthritisTh17 pathwayFamily historyP40 subunitSkin conditionsCell activationArthritisPsoriasisMonoclonal antibodiesPatientsTreatmentReportUstekinumabTh1InterleukinAntibodies
2011
SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.
De Souza A, Solomon G, Strober B. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bulletin Of The NYU Hospital For Joint Disease 2011, 69: 185-7. PMID: 22035400.Peer-Reviewed Original ResearchConceptsHidradenitis suppurativaInflammatory musculoskeletal disordersPrevious ineffective treatmentRefractory SAPHO syndromeSafety of infliximabOral antibioticsComplete remissionSAPHO syndromeFirst doseCutaneous featuresContinued treatmentUnknown etiologyCase reportAcne vulgarisMusculoskeletal disordersIneffective treatmentInfliximabSkin abnormalitiesSyndromeYoung adultsSuppurativaJoint stiffnessTreatmentRemissionArthritis
2010
Disseminated superficial porokeratosis.
Brauer J, Mandal R, Walters R, Solomon G, Kundu R, Strober B. Disseminated superficial porokeratosis. Dermatology Online Journal 2010, 16: 20. PMID: 21163171, DOI: 10.5070/d395d16725.Peer-Reviewed Original ResearchConceptsPsoriatic arthritisSuperficial porokeratosisDiagnosis of porokeratosisOne-week historySetting of immunosuppressionDisseminated superficial porokeratosisCertolizumab pegolPruritic lesionsBiopsy specimenPorokeratosisArthritisDiagnosisPink spotsPegolImmunosuppressionPsoriasisMethotrexateTherapyLesionsExtremitiesWeeksWomen
2007
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Frankel E, Strober B, Crowley J, Fivenson D, Woolley J, Yu E, Xia H, Chiou C, Stevens S. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007, 79: 322-6. PMID: 17500381.Peer-Reviewed Original Research
2006
Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study
Gottlieb A, Kircik L, Eisen D, Jackson J, Boh E, Strober B, Frankel E, Xia H, Stevens S. Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. Journal Of Dermatological Treatment 2006, 17: 343-352. PMID: 17853307, DOI: 10.1080/09546630600967166.Peer-Reviewed Original ResearchConceptsPsoriatic arthritisDermatology clinicBody surface area involvementGlobal assessmentTolerability of etanerceptPatient global assessmentPhysician global assessmentSerious adverse eventsUse of etanerceptSurface area involvementActive psoriatic arthritisWeeks of treatmentBody surface areaEtanercept treatmentExperience diagnosingEtanercept therapyPlaque psoriasisAdverse eventsJoint painArea involvementJoint diseaseDisease scorePatientsArthritisPsoriasis
2004
Successful Treatment of Psoriasis and Psoriatic Arthritis With Etanercept and Methotrexate in a Patient Newly Unresponsive to Infliximab
Strober B. Successful Treatment of Psoriasis and Psoriatic Arthritis With Etanercept and Methotrexate in a Patient Newly Unresponsive to Infliximab. JAMA Dermatology 2004, 140: 366-366. PMID: 15023789, DOI: 10.1001/archderm.140.3.366.Peer-Reviewed Original ResearchSuccessful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab
Strober B. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Journal Of The American Academy Of Dermatology 2004, 50: p147. DOI: 10.1016/j.jaad.2003.10.511.Peer-Reviewed Original Research